Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904163 · ClinicalTrials.gov registry record
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 13
- Enrollment target
NCT00904163: Completed study, sponsored by Stanford University.
NCT00904163 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904163 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-05 |
What the finished NCT00904163 record still lists
NCT00904163 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00904163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00904163 about?
NCT00904163 is a clinical study titled "Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa". Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional c...
What is the current status of trial NCT00904163?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2009-04. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT00904163?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia